Cartesian Therapeutics Inc.
$ 9.51
17.99%
12 Jun - close price
- Market Cap 279,418,000 USD
- Current Price $ 9.51
- High / Low $ 9.75 / 7.90
- Stock P/E N/A
- Book Value -5.19
- EPS -5.80
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.16 %
- ROE -70.29 %
- 52 Week High 15.57
- 52 Week Low 5.60
About
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$34.57
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-03-09 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-03-20 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-03-07 | 2023-11-13 | 2023-08-17 |
| Reported EPS | -0.95 | -2.7065 | -1.38 | -0.77 | -0.65 | -0.5935 | -0.42 | 0.64 | -0.8 | -0.07 | -0.06 | -0.07 |
| Estimated EPS | -0.7 | -0.79 | -0.84 | -0.65 | -0.71 | -0.8257 | -0.55 | -0.09 | -1.42 | -0.04 | -0.06 | -0.08 |
| Surprise | -0.25 | -1.9165 | -0.54 | -0.12 | 0.06 | 0.2322 | 0.13 | 0.73 | 0.62 | -0.03 | 0 | 0.01 |
| Surprise Percentage | -35.7143% | -242.5949% | -64.2857% | -18.4615% | 8.4507% | 28.1216% | 23.6364% | 811.1111% | 43.662% | -75% | 0% | 12.5% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.87 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RNAC
2026-06-13 09:41:10
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) announced the granting of an inducement award to a new employee on June 8, 2026. The award includes an option to purchase 6,100 shares of common stock at an exercise price of $5.86, vesting over four years. This grant aligns with Nasdaq Listing Rules as an inducement for employment and further strengthens the company's team in its mission as a late clinical-stage biotechnology company focused on cell therapy for autoimmune diseases.
2026-06-13 04:11:00
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) recently granted a new employee an inducement award, consisting of an option to purchase 6,100 shares of common stock at an exercise price of $5.86. This grant, approved by the board of directors and vesting over four years, falls under Nasdaq Listing Rules as an inducement for employment. The company is a late clinical-stage biotechnology firm focused on pioneering cell therapy for autoimmune diseases, with its lead asset, Descartes-08, in multiple clinical development phases.
2026-06-12 20:11:40
Cartesian Therapeutics, Inc. announced the granting of an inducement award to a new employee. This award consists of an option to purchase 6,100 shares of the Company's common stock at an exercise price of $5.86, vesting over four years. The grant was made under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement for the employee to join the company.
2026-06-12 20:09:40
Cartesian Therapeutics (NASDAQ: RNAC) has granted a new employee an inducement stock option for 6,100 shares at an exercise price of $5.86. The option vests through June 8, 2030, with 25% vesting after one year and the remainder in monthly installments, and has a ten-year term. This grant was issued under Nasdaq Rule 5635(c)(4) as a material inducement for employment.
2026-06-11 22:09:23
Cartesian Therapeutics, Inc. (RNAC) experienced a significant 10.3% price increase, closing at $1.92 in the latest trading session, surpassing both the S&P 500 and its sector's daily gains. Despite this rise, the stock remains below its 52-week high and has an unfavorable average brokerage recommendation, suggesting potential for further price movement. Investors are advised to monitor an upcoming earnings report for more insights into the company's future performance.
2026-06-10 08:40:01
Cartesian Therapeutics has announced a strategic licensing agreement with WestGene Biopharma to advance the development of novel in vivo CAR
